Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 19/20 | 0.85 |
| ▸ | PDE1A | P54750 | 8/20 | 0.85 |
| ▸ | PDE1B | Q01064 | 8/20 | 0.85 |
| ▸ | PDE1C | Q14123 | 8/20 | 0.85 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.54 |
| ▸ | PDE6A | P16499 | 2/20 | 0.54 |
| ▸ | PDE2A | O00408 | 1/20 | 0.54 |
| ▸ | PDE6D | O43924 | 1/20 | 0.54 |
| ▸ | PDE9A | O76083 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | PDE6G | P18545 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | PDE6B | P35913 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6332617 | 1.00 | PDE5A (0.85) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL5901813 | 1.00 | PDE5A (0.85) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL6332323 | 0.99 | PDE5A (0.86) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL30493634 | 0.92 | PDE5A (1.00) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL5613 | 0.92 | PDE5A (1.00) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL5902783 | 0.85 | PDE5A (0.70) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL973661 | 0.85 | PDE5A (0.86) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL6332643 | 0.84 | PDE5A (0.66) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL6334314 | 0.84 | PDE5A (0.66) | PDE5APDE1APDE1BPDE1CHDAC1 | |
| SCHEMBL6330112 | 0.84 | PDE5A (0.66) | PDE5APDE1APDE1BPDE1CHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098207-B2 | Imidazotriazinones and the use thereof | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-29 | — | — | US | disclosed |
| US-20050267112-A1 | Novel imidazotriazinones and the use thereof | BAYER AKTIENGESELLSCHAFT (US) | 2005-12-01 | — | — | US | disclosed |
| US-6943163-B2 | 7-Alkyl and cycloalkyl-substituted imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2005-09-13 | — | — | US | disclosed |
| US-6878708-B2 | Imidazotriazinones and the use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2005-04-12 | — | — | US | disclosed |
| US-20050049250-A1 | 7-Aikyl and cycloalkyl-substituted imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-03 | — | — | US | disclosed |
| EP-1280805-B1 | NOVEL IMIDAZOTRIAZINONES AND THE USE THEREOF | BAYER HEALTHCARE AG (DE) | 2005-02-09 | — | — | EP | disclosed |
| US-6838459-B1 | 7-alkyl-and cycloalkyl-substituted imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2005-01-04 | — | — | US | disclosed |
| US-20040097498-A1 | Novel imidazotriazinones and the use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
| EP-1280805-A1 | NOVEL IMIDAZOTRIAZINONES AND THE USE THEREOF | Bayer Aktiengesellschaft (DE) | 2003-02-05 | — | — | EP | disclosed |
| US-6476029-B1 | 7-alkyl- and cycloalkyl-substituted imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2002-11-05 | — | — | US | disclosed |
| WO-2001064677-A1 | NOVEL IMIDAZOTRIAZINONES AND THE USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-07 | — | — | WO | disclosed |
| EP-1090003-A1 | 7-ALKYL- AND CYCLOALKYL-SUBSTITUTED IMIDAZOTRIAZINONES | Bayer Aktiengesellschaft (DE) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067244-A1 | 7-ALKYL- AND CYCLOALKYL-SUBSTITUTED IMIDAZOTRIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097498-A1 | Novel imidazotriazinones and the use thereof | CYP4F3, CYP4F2, CYP3A7 | PDE5A 469/4885PDE1A 407/4885PDE1B 346/4885 |
| US-20050267112-A1 | Novel imidazotriazinones and the use thereof | CYP3A7, CYP4F2, CYP4F3 | PDE5A 338/4885PDE1A 376/4885PDE1B 285/4885 |
| US-20050049250-A1 | 7-Aikyl and cycloalkyl-substituted imidazotriazinones | PDE3A, PDE2A, PDE3B | PDE5A 6/4885PDE1A 35/4885PDE1B 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.